Last reviewed · How we verify
Anti-NGF AB
Anti-NGF AB is a NGF antagonist Biologic drug developed by Pfizer. It is currently in Phase 2 development for Neuropathic pain.
Antagonist of nerve growth factor
Anti-NGF AB is being studied in clinical trials for the treatment of Neoplasms and Bone Metastases. The primary purpose of these trials is to assess the safety of Anti-NGF AB in cancer patients.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression). -
Big-pharma sponsor
+3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Anti-NGF AB |
|---|---|
| Sponsor | Pfizer |
| Drug class | NGF antagonist |
| Target | NGF |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Anti-NGF AB works by blocking the action of nerve growth factor, a protein involved in the growth and maintenance of nerve cells.
Approved indications
- Neuropathic pain
Common side effects
- Injection site reaction
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-NGF AB CI brief — competitive landscape report
- Anti-NGF AB updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Anti-NGF AB
What is Anti-NGF AB?
How does Anti-NGF AB work?
What is Anti-NGF AB used for?
Who makes Anti-NGF AB?
What drug class is Anti-NGF AB in?
What development phase is Anti-NGF AB in?
What are the side effects of Anti-NGF AB?
What does Anti-NGF AB target?
Related
- Drug class: All NGF antagonist drugs
- Target: All drugs targeting NGF
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Neuropathic pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing